Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28111758 | 0.98 | S1PR1 (0.57) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| SCHEMBL4419378 | 0.98 | S1PR1 (0.57) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| SCHEMBL27551089 | 0.98 | S1PR1 (0.57) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| SCHEMBL27287754 | 0.98 | S1PR1 (0.57) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| SCHEMBL18531651 | 0.98 | CYP1A2 (0.61) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| Bromide SCHEMBL28654872 | 0.96 | S1PR1 (0.56) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| Bromide SCHEMBL31318389 | 0.94 | S1PR1 (0.55) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| SCHEMBL15508580 | 0.94 | CYP1A2 (0.60) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| SCHEMBL292866 | 0.94 | S1PR1 (0.54) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 | |
| SCHEMBL14539275 | 0.92 | S1PR1 (0.56) | CYP1A2S1PR1S1PR3S1PR5CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027323-A | Poly (aryl methyl piperidine) polymer, preparation method and anion exchange membrane | 西湖大学 | 2024-05-14 | — | — | CN | claimed |
| CN-118027323-A | Poly (aryl methyl piperidine) polymer, preparation method and anion exchange membrane | 西湖大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-112210230-A | Dye dispersion composition for color filter and dye dispersion resist composition for color filter | 阪田油墨股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-1620400-B1 | piperidinylmethylpiperidine derivatives and their use as chemokine modulators | ASTRAZENECA AB (SE) | 2012-12-05 | — | — | EP | disclosed |
| US-20090118513-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-7495013-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-02-24 | — | — | US | disclosed |
| EP-1625114-B1 | Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070032523-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20060264463-A1 | Chemical compounds | MEDTECH CONVERGENCE FUND, L.P. | 2006-11-23 | — | — | US | disclosed |
| CN-1768037-A | Chemical compounds. | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | CN | disclosed |
| EP-1620400-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004087659-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| US-5760235-A | DIPEPTIDES BASED ON PROLINE OR PIPECOLIC ACID AND ARGININE ALDEHYDE | GYOGYSZERKUTATO INTEZET KFT. (HU) | 1998-06-02 | — | — | US | disclosed |
| EP-0629212-B1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF | GYOGYSZERKUTATO INTEZET (HU) | 1997-10-08 | — | — | EP | disclosed |
| EP-0546583-B1 | Piperazinyl-and piperidinyl-cyclohexanols | BRISTOL MYERS SQUIBB CO (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0629212-A1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF. | GYOGYSZERKUTATO INTEZET (HU) | 1994-12-21 | — | — | EP | disclosed |
| WO-1993018060-A1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF | Gyógyszerkutató Intézet Kft. (HU) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118513-A1 | Chemical Compounds | CCR3, CCR1, CCR4 | CYP1A2 714/4885S1PR1 78/4885S1PR3 63/4885 |
| US-20070032523-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CYP1A2 787/4885S1PR1 63/4885S1PR3 56/4885 |
| US-20060264463-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CYP1A2 680/4885S1PR1 74/4885S1PR3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.